Informations générales (source: ClinicalTrials.gov)
Platino-resistance in Ovarian Cancer (PlatinOv)
Interventional
N/A
Institut Claudius Regaud (Voir sur ClinicalTrials)
mars 2020
mars 2030
07 août 2024
Prospective, monocentric study aiming to identify factors involved in platinum
based-chemotherapy resistance in patients with epithelial ovarian cancer (all stages).
Patients will receive treatment (platinum based-chemotherapy) according to the standard
practices.
A prospective database and an associated biological collection will be performed during 5
years:
- For each patient: clinical, biological, epidemiological and therapeutic treatment
data will be collected during the standard therapeutic care.
- Biological samples (blood samples, tumor biopsy specimens and ascites samples) will
be collected for all patients. These samples will be collected at the same time as
those taken in standard practice (no additional biopsy will be performed for the
study).
Study participation of each patient will be 5 years.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Institut Universitaire du Cancer de Toulouse - Oncopole - Toulouse - France | Gwenaël FERRON | Contact (sur clinicalTrials) | |||
Critères
Femme
Inclusion Criteria:
1. Age ≥ 18 years old
2. Epithelial ovarian cancer at initial diagnosis (all stages)
3. Curative treatment (exeresis surgery) not yet initiated excepted neo-adjuvant
treatment
4. Indication of platinum based-chemotherapy
5. Patient affiliated to the french social security system
6. Patient must provide written informed consent prior to inclusion in the study and
any study-specific procedure
1. Age ≥ 18 years old
2. Epithelial ovarian cancer at initial diagnosis (all stages)
3. Curative treatment (exeresis surgery) not yet initiated excepted neo-adjuvant
treatment
4. Indication of platinum based-chemotherapy
5. Patient affiliated to the french social security system
6. Patient must provide written informed consent prior to inclusion in the study and
any study-specific procedure
1. Non-epithelial ovarian tumor, borderline ovarian tumor
2. Patient with recurrent disease
3. Exploratory surgery not performed at the "Institut Universitaire du Cancer de
Toulouse - Oncopole (IUCT-O)"
4. Pregnant or breastfeeding women
5. Any psychological, familial, geographical or sociological condition potentially
preventing the medical follow-up and/or study procedures
6. Patient who has forfeited his/her freedom by administrative or legal award or who is
under legal protection (curatorship and guardianship, protection of justice)